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Edited by Veli-Pekka LehtoAbstract Several anti-angiogenic factors are derived from pro-
teolytic processing of large molecules including endostatin from
type XVIII collagen and angiostatin from plasminogen. In previ-
ous studies we showed that neostatin-7, the C-terminal 28 kDa
endostatin-spanning proteolytic fragment, is generated from
the proteolytic action of matrix metalloproteinase matrilysin
(MMP)-7 on type XVIII collagen. Now, we report a second
member of the neostatin family of proteins, neostatin-14. Given
the small quantities of neostatin-7 and -14 generated by the
breakdown of naturally occurring collagen XVIII (using
MMP-7 and -14, respectively), we used two other approaches
to characterize the anti-angiogenic properties of these molecules:
murine recombinant neostatin in vitro, and gene therapy. We
demonstrate that murine recombinant neostatin-7 inhibits calf
pulmonary artery endothelial cell proliferation and that microin-
jection of neostatin-7 and neostatin-14 naked DNA into the cor-
neal stroma of mice results in signiﬁcant reduction of basic
ﬁbroblast growth factor-induced corneal neovascularization.
These results provide supportive evidence of the possible anti-
angiogenic eﬀect of neostatins.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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metalloproteinas; MMP-7; MMP-141. Introduction
Type XVIII collagen is a member of the multiplexin subfam-
ily of collagens. It is a proteoglycan composed largely of hep-
aran sulfate side chains [1]. It is located mainly in the
perivascular regions around the blood vessels in the intestinal
villi, choroids plexus, skin, liver, and kidneys and is also pres-
ent in adult and embryonic basal laminae [2,3]. In ocular tis-
sues, type XVIII collagen is present in the retinal basal
lamina, pigment epithelial basement lamina, and periocular
mesenchyme [4]. We have also observed that collagen type
XVIII is present in the corneal epithelial basement membraneq Supported by the New England Corneal Transplant Research Fund,
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doi:10.1016/j.febslet.2005.05.043as well as in the stromal side of Descemets membrane [5]. Inci-
sional wounds in mouse corneal tissue resulted in enhanced
collagen XVIII mRNA and protein expression along the
wound edges [6].
Type XVIII collagen plays a role in ocular structure and
neovascularization (NV) [7]. Mice lacking type XVIII collagen
have ocular defects, including delayed regression of the hyaloid
vasculature, poor outgrowth of the retinal vessels, fragile irises,
and development of ciliary body atrophy [8]. Patients with type
XVIII collagen mutations displayed Knobloch syndrome. This
syndrome includes vitreoretinal degeneration, retinal detach-
ment, high myopia, and macular abnormalities [9–11]. Most
mutants with premature protein translation showed a deﬁ-
ciency of collagen XVIII and endostatin.
Endostatin, the 20-kDa peptide at the carboxyl terminal of
type XVIII collagen, has tumor-suppressing properties and po-
tent anti-angiogenic activity [12–17]. In vitro studies show that
the hinge domain of type XVIII collagen, located between the
association domain and the endostatin domain, is cleaved by
elastase and/or cathepsin L to release endostatin from the type
XVIII collagen [18,19]. We have reported that one of the ma-
trix metalloproteinases (MMPs) expressed in the cornea during
normal and wound-healing conditions, matrilysin (MMP-7),
cleaves the NC1 hinge region of type XVIII collagen at a
location upstream from the cathepsin L cleavage site to
generate neostatin-7 (28 kDa endostatin-spanning fragment)
[5,6,20,21]. Here we demonstrated that another MMP (MMP-
14) also cleaves type XVIII collagen to generate 23 kDa
neostatin (neostatin-14). We attempted to determine whether
murine neostatin-7 and neostatin-14 have anti-angiogenic
potential. We also performed gene therapy using neostatins
-7 and -14 in the cornea to assay their inhibitory eﬀects on
corneal NV. We demonstrate that neostatin-7 and -14 naked
DNA prevent basic ﬁbroblast growth factor (bFGF)-induced
corneal NV in the mouse model.2. Materials and methods
2.1. Anti-type XVIII collagen antibodies
Antibodies used in this project include those generated in our labo-
ratory against the NC1 domain (anti-hinge region) and the endostatin
domain (anti-endostatin) as described by Lin et al. [5] and commer-
cially available antibodies.
2.2. Generation of recombinant His-endostatin and His-neostatin-7
Mouse collagen XVIII cDNAs containing endostatin and neostatin
were ampliﬁed through polymerase chain reaction (PCR) from the
NC1 fragment and subcloned into the pET28A vector (Novagen,blished by Elsevier B.V. All rights reserved.
Fig. 1. MMP-7 cleaved NC1 fragment of collagen XVIII. (A)
Endostatin containing fragments were generated by various MMPs.
Puriﬁed recombinant NC1 fragments were incubated with MMP-2, -7,
-9, and -14 for 20 h and immunoblotted with anti-mouse endostatin
antibodies. Fragments of neostatin-14 have been sequenced (N-
terminal amino acid residues are xVHLRPARPG). (B) Diagram of
collagen XVIII cleaved by MMP-7 and MMP-14. (x = unknown
amino acid, V = Valine, H = Histidine, L = Leucine, R = Arginine,
P = Proline, A = Alanine, and G = Glycine).
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GCACGGAATTCCAGGTGGCTGCTTTCC, 5 0 XVIII neostatin-14
GTTCCACATCACCACGAATTCTATGTGCACCTGCCGCCAG-
CCCGC, 5 0 XVIII endo CACCACAGTTCCTATGAATTCCTGC-
CGCCAGCCCGC and 3 0 XVIII endo CTGCCACCCTAGCTG-
GCGGCCGCCTATTTGGAGAAAGAGG. These constructs were
transformed into Escherichia coli (BL21DE3, Novagen, Madison,
WI), and a single colony was isolated for each construct [22]. The bac-
teria were grown to semi-log phase isopropyl thiogalactopyranoside
(IPTG, Gibco BRL, Gaithersburg, MD) at which point they were in-
duced with 0.3 mM of IPTG to produce His-endostatin and His-neost-
atin. The bacteria were lysed with 8 M urea in PBS and the protein was
isolated using a Ni-bead column (Invitrogen, Carlsbad, CA). His-
endostatin and His-neostatin were eluted with 40 mM imidazole and
dialyzed against PBS. The purity of the His-fusion proteins was deter-
mined by Coomassie Brilliant blue staining and Western blot analysis.
In addition, cDNA fragments of type XVIII collagen (endostatin and
neostatin) were subcloned into eukaryotic expression vectors (pEF;
Invitrogen, Carlsbad, CA) with an Igk leader and myc-epitope peptide
sequences [23].
2.3. MMP cleavage assays and puriﬁcation of neostatins-7 and -14
One hundred nanograms of C-ﬂag-tagged type XVIII collagen
NC1 fragments were cleaved with various activated MMPs (MMPs
-2, -7, -9, and -14). Proteolytic fragments were analyzed by Western
blot analysis with anti-endostatin or anti-C-ﬂag (M2) antibody (Sig-
ma, St. Louis, MO). MMP-7 cleavage of NC1 fragments was per-
formed at various pH conditions (pH 5.5, 6.5, 7.5) to determine
the eﬃcacy of generating the corresponding MMP-derived neostatin
(neostatin-7).
2.4. CPAE proliferation assay
Calf pulmonary artery endothelial (CPAE) cells (ATCC, Manassas,
VA) were grown to conﬂuence in Dulbeccos modiﬁed Eagles medium
(DMEM) with 10% fetal calf serum (FCS; Sigma–Aldrich Corp., St.
Louis, MO) and kept conﬂuent for 48 h. The cells were harvested by
trypsinization at 37 C for 5 min. A suspension of 2000 cells in DMEM
with 0.5% FCS was added to each well of a 96-well plate coated with
10 lg/ml ﬁbronectin and incubated for 24 h at 37 C. The medium was
removed and replaced with DMEM containing 0.5% FCS (unstimu-
lated cells) or 10% FCS (stimulated and treated cells) in the presence
or absence of recombinant endostatin and neostatin. After the 48-h
proliferation period, cell density was determined using a Formazin
kit (Promega, Fitchburg Center, WI). Controls were cultured in a sim-
ilar fashion.
2.5. Corneal pocket assay with bFGF in the presence of naked DNA
(pEF-neostatin-7, pEF-neostatin-14, pEF-endostatin, and vector
control)
A 0.5-mm incision perpendicular to the mouse corneal surface tra-
versing the epithelium and anterior stroma was performed with a
1/2-in., 30-gauge needle (Becton Dickinson, Franklin Lakes, NJ).
A 1/2-in., 33-gauge needle attached to a 10-ll gas-tight syringe
(Hamilton, Reno, NV) was introduced into the corneal stroma
and advanced toward an area 2/3 of the distance between the limbus
and the corneal center and close to the corneal center. Turning the
bevel toward the center of the cornea, plasmid (2 lg of pEF, pEF-
endostatin, and pEF-neostatins) solution was forcibly injected into
the stroma.
Corneal micropocket assay, as described by Kato et al. [24], was car-
ried out three days after corneal naked DNA injection. Brieﬂy, wild-
type mice (C57BL/6) were anesthetized by an intraperitoneal injection
of ketamine and xylazine, and proparacaine HCl eye drops were used
for local anesthesia [24]. Corneal micropockets were created with a
modiﬁed von Graefe knife. Uniformly sized hydron pellets containing
80 ng of human bFGF (R&D Systems, Minneapolis, MN) and 40 lg
of sucrose aluminum sulfate were implanted into corneal pockets at
day 4 after naked DNA injection [25,26]. Oﬂoxacin eye drops were in-
stilled after surgery. The eyes were examined and photographed on
days 0, 1, 4 and 7 post-pellet implantation by slit lamp microscopy (Ni-
kon, Tokyo, Japan). Color images were magniﬁed 100· to allow pre-
cise measurement of corneal NV. The neovascular area was
calculated using a modiﬁed NIH imaging program to correct for par-
allax as described by Kure et al. [20].3. Results
3.1. Cleavage of the NC1 region with diﬀerent MMPs
Recombinant NC1 fragments of collagen XVIII were gen-
erated in cultured 293T cells as described by Sasaki et al.
(Fig. 1A) [27]. The recombinant NC1 fragments were isolated
in serum-free medium with heparin sepharose. Fragments
were incubated with MMP-2, -7, -9, and -14 (Fig. 1A) at a
concentration of 0.1 lg protein/0.1 lg active enzyme. Treat-
ment of the recombinant NC1 fragment of type XVIII colla-
gen with MMP-2 and -9 and the control did not produce
NC1 degradation products. However, MMP-7 and MMP-14
cleaved the recombinant NC1 fragment to produce neosta-
tin-7, neostatin-14, and several endostatin-containing frag-
ments. Fragments of MMP-14 cleavage of NC1 were
subjected to Edman degradation protein sequencing. One
of the sequenced fragments had an N-terminal sequence of
xVHLRPARPG (Fig. 1B). The MMP-14 cleavage site of
the NC1 fragment of type XVIII collagen residue is located
between the MMP-7 and cathepsin L cleavage sites. The
MMP-14 cleavage site of NC1 fragments agrees with the pro-
tease-sensitive site of naturally occurring type XVIII collagen
in the blood.
Fig. 3. Inﬂuence of pH and cathepsin L on MMP-7 cleavage of
recombinant NC1. (A) MMP-7 cleavage of type XVIII has been
performed at various pHs (lane 1, control, pH 7.5; lane 2, pH 5.5; lane
3, pH 6.5; and lane 4, pH 7.5). (B) Cathepsin L did not interfere with
the cleavage of NC1 fragments by MMP-7. Recombinant NC1 was
isolated by heparin sepharose and incubated with cathepsin L (lane 2),
MMP-7 (lane 3), and cathepsin L plus MMP-7 (lane 4) at pH 7.5 for
4 h (lane 1 = control).
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eﬀects on CPAE proliferation assay
The schematic diagram of type XVIII collagen, NC1, neost-
atins, and endostatin is depicted in Fig. 2A. His-endostatin
and His-neostatin-7 were generated from bacterial lysate and
puriﬁed using Ni-beads. They were then eluted with 40 mM
imidazole. The eluted His-endostatin and His-neostatin-7 were
analyzed with SDS–polyacrylamide gel electrophoresis (SDS–
PAGE). This resulted in the production of Coomassie Brilliant
blue staining bands corresponding to the molecular weight of
His-endostatin (20 kDa) and His-neostatin-7 (28 kDa,
Fig. 2B). His-endostatin and His-neostatin-7 were character-
ized by Western blot analysis with anti-endostatin antibodies.
His-fusion proteins showed molecular weight bands of 20 kDa
(Fig. 2C, lane 1) and 28 kDa (Fig. 2C, lane 2) representing His-
endostatin and His-neostatin-7, respectively.
To compare the eﬀects of recombinant endostatin and neost-
atin-7 on vascular endothelial cell proliferation in vitro, we
added 2.5 lg/ml of endostatin with 10% FCS and 2.5 lg/ml
neostatin-7 with 10% FCS to the cultured CPAE cells (Fig.
2D). As shown in Fig. 2D, recombinant neostatin-7 and re-
combinant endostatin inhibited CPAE proliferation,
OD495 = 0.378 ± 0.04 (bar 3) and OD495 = 0.375 ± 0.015 (bar
2), respectively, when compared to that of 10% FCS control,
OD495 = 0.46 ± 0.02 (bar 1).
3.3. PH aﬀects MMP-7 cleavage of NC1 fragments of type
XVIII collagen
To determine whether pH has an eﬀect on the enzymatic
processing of MMP-7 and cathepsin L on NC1 fragments of
Type XVIII collagen, NC1 fragments were incubated with
MMP-7 at various pHs (Fig. 3A; pH 5.5, 6.5, and 7.5) for
20 h. Extensive degradation of NC1 occurred at lower pHs
(lanes 2 and 3). In addition, recombinant NC1 fragments were
incubated with MMP-7 alone (Fig. 3B, lane 2), MMP-7 in
combination with cathepsin L (Fig. 3B, lane 3) and the controlFig. 2. Recombinant His-endostatin and His-neostatin-7 were produced by E
collagen showing the relationship of the NC1 region, neostatin-7 and -14, and
using Ni beads and eluted by 40 mM imidazole and then stained with Cooma
(lane 1) and neostatin (lane 2) using the anti-endostatin antibodies. (D) Recom
proliferation assay when compared to that of control (lane 1). (lane 1, 10% FC
neostatin-7).(lane 1). NC1 fragments were processed to generate several
endostatin-containing fragments. Accumulation of 28 kDa
fragments and diminished NC1 fragments was found in lanes
2 and 3 but not in lane 1 (Fig. 3B).
3.4. Naked DNA, pEF-endostatin, pEF-neostatins, blocked
bFGF-induced corneal NV
Naked DNA has been eﬀectively used for the delivery of
DNA into mouse corneas. To assay if neostatin-7 and neosta-
tin-14 can inhibit bFGF-induced corneal NV, mouse corneas
were injected with naked DNA of pEF, pEF-endostatin,
pEF-neostatin-7, and pEF-neostatin-14. A bFGF pellet
(80 ng) was implanted into mouse corneas 72 h post DNA
injection (pEF, pEF-endostatin, pEF-neostatin-7, and. coli and isolated by Ni beads. (A) Schematic illustration of type XVIII
endostatin. (B) Recombinant endostatin and neostatin-7 were isolated
ssie Brilliant blue. (C) Western blot analysis of recombinant endostatin
binant endostatin-7 (lane 2) and neostatin-7 (lane 3) diminished CPAE
S; lane 2, 10% FCS + 2.5 lg/ml endostatin; lane 3, 10% FCS + 2.5 l/ml
Fig. 4. Eﬀect of neostatin-7 and neostatin-14 on bFGF-induced
corneal NV. Mouse corneas were injected with naked DNA [pEF
vector control (n = 7), pEF-endostatin (n = 7), pEF-neostatin-14
(n = 4), pEF-neostatin-7 (n = 7) 3 days before bFGF pellet implanta-
tion. Corneal NV was observed at days 4 and 7. The areas of corneal
NV in endostatin and neostatin groups were measured and percent NV
relative to control at days 4 and 7 were calculated. (Asterisks indicate
statistically signiﬁcant diﬀerences in comparison to vector controls;
P < 0.05).
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lated with standard error of the mean (S.E.M.). As compared
to control pEF DNA injection, percent NV at days 4 and 7
were 27.4 ± 4.3%, 26 ± 9% with pEF-endostatin DNA injec-
tion, 65 ± 10%, 21 ± 8.7% with pEF-neostatin-14 DNA injec-
tion, and 85 ± 36%, 53 ± 14% with pEF-neostatin-7 DNA
injection. Diminished corneal NV was observed after pEF-
endostatin, pEF-neostatin-7, and pEF-neostatin-14 DNA
injection at days 4 and 7 as compared to controls (Fig. 4).
Additional controls in which mouse corneas were injected with
naked DNA only (pEF, pEF-endostatin, and pEF-neostatin-7)
without bFGF pellet implantation showed no evidence of cor-
neal NV at days 4 and 7.4. Discussion
Neostatin-7 is an MMP-7-derived endostatin-spanning frag-
ment of type XVIII collagen. Lin et al. [5] have demonstrated
that MMP-7 cleaves corneal derived type XVIII collagen at the
hinge domain to generate a 28 kDa fragment [5]. We have ob-
served that MMP-14 cleaves the NC1 fragment of type XVIII
to generate a 23 kDa fragment (neostatin-14). Neostatins are
among several naturally occurring endostatin-spanning frag-
ments in human blood. Our previous data of the N-terminal
sequence of corneal MMP-7-derived neostatin and the data
presented herein of the N-terminal sequence of MMP-14-de-
rived neostatin correspond in identity to the puriﬁed endo-
statin-spanning fragment derived from circulating human
blood.
It is likely that MMP-7 and -14 may have a role in the reg-
ulation of NV and tumorigenesis. We hypothesize that this
may be due to cleavage of anti-angiogenic precursors and the
production of anti-angiogenic molecules including, but not
limited to, neostatin-7 and -14. MMP-7 has a substrate cleav-age preference for a leucine residue in the p1 0 region and a
hydrophobic residue in the p1 0 position. In type XVIII colla-
gen, our data demonstrated that the active MMP-7 enzyme
cleaves the 34-kDa NC1 fragment. The resultant 28-kDa
fragment was subjected to N-terminal protein sequencing
and was shown to have an N-terminal amino acid sequence
of LxDSNPYPRR, located in the hinge region of the NC1
domain. Similarly, the substrate speciﬁcity of MMP-14 has
demonstrated that the amino acid residues of p1 and p2 are
hydrophobic residues [28]. These results are in agreement with
our sequenced N-terminal hydrophobic amino acid residues of
neostatin-14 (xVHLRPARPG).
MMP-7 has also been demonstrated to cleave plasminogen
to generate angiostatin [29]. MMP-7 hydrolyzes human plas-
minogen to generate 42- and 38-kDa fragments that have the
N-terminal sequence VVLLPNVETP corresponding to the
amino acid sequence 467–476 of plasminogen between kringle
domains 4 and 5. These MMP-7-derived angiostatin fragments
have anti-angiogenic properties.
In the cornea, the balance between angiogenic and anti-
angiogenic factors holds sway over the avascular milieu of
the cornea and is governed by many variables. Injurious stim-
uli generate a multitude of responses aimed at the proteolysis
of precursors to generate factors which tilt the balance toward
the production or prevention of NV. Our previously published
data showed up-regulation of MMP-7 in wild-type animal
wounding models and an increased vascular response in
MMP-7-deﬁcient littermates [20]. It is our hypothesis that
MMP-7- and MMP-14-derived neostatin may be part of an ar-
ray of factors that prevent new vessel formation ostensibly
independent of endostatin.
Endostatin, a proteolytic fragment of type XVIII collagen,
has been shown to be generated by secreted cathepsin L [18].
Endostatin inhibits cell migration and cell proliferation, de-
creases tumor size, and enhances vascular endothelial cell
apoptosis in vitro and in vivo [15,16,30–33]. The mechanisms
involved in the eﬀect of endostatin on vascular endothelial cells
have been extensively investigated and several endostatin-asso-
ciated molecules have been isolated and characterized, includ-
ing MMP-2, L-selectin, integrin avb3, VEGF receptor (KDR/
ﬂk-1), tropomyosin, glypican, and laminin [34–40]. Endostatin
binds to these cellular counterparts, which may facilitate the
function of endostatin in vascular endothelial cell prolifera-
tion. We hypothesize that the anti-angiogenic activity of neost-
atins may result from neostatin-associated molecules that may
or may not overlap with those of endostatin. Additional exper-
iments comparing the neostatin- and endostatin-associated
molecules will shed light on this important issue. The signiﬁ-
cance of these future experiments is that diﬀerences in the
activities and diﬀerences in the associated molecules of the
neostatins and endostatin may provide new target molecules
for the treatment of corneal and ocular angiogenic disorders
as well as benign and malignant tumors.
Our data suggest that certain similarities may exist between
the functions of neostatin and endostatin. The observation
that neostatin-7 diminished serum-induced vascular endothe-
lial cell proliferation in vitro and the observation that naked
DNA injection of neostatin-7 and -14 inhibited bFGF-induced
corneal NV in vivo suggest that MMP-7 and MMP-14
cleavage of type XVIII collagen may play a role in the regula-
tion of angiogenesis via the production of neostatin-7 and
neostatin-14. The information we have generated may not only
J.-H. Chang et al. / FEBS Letters 579 (2005) 3601–3606 3605help us understand the mechanisms of the maintenance of
corneal avascularity during wound healing, but may also lead
to potential anti-angiogenic treatments aimed at the preven-
tion of progressive angiogenesis-dependent disorders such as
ocular neovascular disorders and neoplasms.References
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